aKLmRNA-mediated Protein Replacement Therapy

Exclusion criteria

• ✕. Known of suspected allergy to IMP or related procedure
• ✕. Known or suspected allergy, or history of anaphylaxis, to vaccines or their excipients, if considered relevant by the Investigator
• ✕. Contraindications for the use of emergency treatments
• ✕. Clinically relevant findings at screening, e.g., active diseases of any kind particularly infections
• ✕. History of chronic alcohol or drug abuse/ dependence within the past 5 yearsUse of any prescription or over-the-counter medication within 7 days prior to first dosing or planned use during the study period, with the exception of medications considered medically necessary and administered at a stable dose and regimen. Stable medication is defined as medication for which no initiation, discontinuation, or dose adjustment has occurred for at least 3 monthsprior to first dosing and for which no change is anticipated during the study period. Occasional use of paracetamol (acetaminophen) and/or ibuprofen is permitted at the discretion of the investigator.
• ✕. Employee at the study site, spouse/partner or relative of any study staff (e.g., investigator, sub investigators, or study nurse) or employee of the Sponsor
• ✕. Known or suspected pregnancy, planned pregnancy of lactation
• ✕. Clinically significant unstable psychiatric illness in the past 6 months